Source comparison
Best Tesamorelin Dosage HIV Lipodystrophy 2026: Clinical Trial Comparison
EGRIFTA-1 (Lancet 2010) 2mg daily SC 26 weeks 15.2% vs 4.9% placebo 32% (mostly injection site reactions) Gold standard. Establishes 2mg as optimal dose with significant VAT reduction and acceptable safety profile EGRIFTA-2 (AIDS 2011) 18.1% vs 5.3% placebo 29
This comparison does not assign a generated winner or score.
- EGRIFTA-1 (Lancet 2010)
- 2mg daily SC
- 26 weeks
- 15.2% vs 4.9% placebo
- 32% (mostly injection site reactions)
- Gold standard. Establishes 2mg as optimal dose with significant VAT reduction and acceptable safety profile
- EGRIFTA-2 (AIDS 2011)
- 18.1% vs 5.3% placebo
- 29% (arthralgia, peripheral oedema common)
- Replication cohort confirming dose consistency. No additional benefit observed in patients attempting self-titration above protocol dose
- Extension Study (JID 2012)
- 52 weeks
- 20.4% cumulative reduction
- 35% (no new safety signals beyond week 26)
- Demonstrates durability. VAT continues declining through week 30 then stabilises, confirming plateau effect